News & Updates
Showing Endocrinology articles
Showing
Semaglutide benefits extend to HFpEF patients with T2D
The weight loss and heart failure (HF) benefits of semaglutide extend to patients with obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) in the STEP-HFpEF DM trial, fuelling speculation that semaglutide may have cardiovascular effects beyond weight loss.
Semaglutide benefits extend to HFpEF patients with T2D
04 May 2024
Smartphone app helps control blood sugar in people at risk of T2D
Use of a smartphone application (app) and an intermittently scanned continuous glucose monitoring (isCGM) results in better glycaemic control, lower carbohydrate intake, and weight loss in people at increased risk of type 2 diabetes (T2D), reports a study.
Smartphone app helps control blood sugar in people at risk of T2D
29 Apr 2024
Hyperglycaemia, dyslipidemia up risk of diabetic kidney disease
A recent study has identified six common metabolic profiles among patients with type 2 diabetes (T2D). In addition, severe hyperglycaemia and moderate dyslipidemia are associated with an increased risk of diabetic kidney disease (DKD).
Hyperglycaemia, dyslipidemia up risk of diabetic kidney disease
23 Apr 2024
A sock to detect diabetic, CV complications?
A study presented at EHRA 2024 demonstrated the potential of a sock fitted with a ballistocardiogram (BCG) sensor to predict diabetic complications by identifying foot pressure distribution patterns, as well as to detect cardiovascular issues.
